Professor Sergio Rutella attended the 2023 European Haematology Association Conference in Germany in June, where he delivered a talk on natural killer (NK) cell therapy for patients with acute myeloid leukaemia. This study was undertaken in collaboration with academics from Washington University and with Wugen, a pharmaceutical company that are sponsoring an early-phase clinical trial of a specific population of immune cells expected to efficiently kill tumour cells. The preliminary results are promising and show that NK cells can induce responses in approximately 45% of its study subjects.
Professor Rutella also attended the Tumour Immunology Meets Oncology (TIMO) XVII Symposium in Germany, where he presented evidence generated by his lab that points to immune system dysfunction as a key determinant of poor clinical outcomes in acute myeloid leukaemia.
|